These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12481397)
21. Mechanism of central nervous system toxicity by irinotecan. Kovacic P Med Hypotheses; 2006; 67(4):997. PubMed ID: 16790317 [No Abstract] [Full Text] [Related]
22. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer]. Guan ZZ Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384 [No Abstract] [Full Text] [Related]
23. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062 [No Abstract] [Full Text] [Related]
24. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11). Boisseau M; Bugat R; Mahjoubi M Eur J Cancer; 1996 Apr; 32A(4):737-8. PubMed ID: 8695285 [No Abstract] [Full Text] [Related]
25. Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11). Duong Van Huyen JP; Bloch F; Attar A; Levoir D; Kreft C; Molina T; Bruneval P Dig Dis Sci; 1998 Dec; 43(12):2649-51. PubMed ID: 9881496 [No Abstract] [Full Text] [Related]
26. Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer. Abu-Amna M; Hassoun G; Hadad S; Haim N; Bar-Sela G Clin Colorectal Cancer; 2015 Dec; 14(4):e49-51. PubMed ID: 26051444 [No Abstract] [Full Text] [Related]
27. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613 [TBL] [Abstract][Full Text] [Related]
28. Oral irinotecan for treatment of pediatric solid tumors: ready for prime time? Wagner LM Pediatr Blood Cancer; 2010 May; 54(5):661-2. PubMed ID: 20108333 [No Abstract] [Full Text] [Related]
29. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Innocenti F Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625 [No Abstract] [Full Text] [Related]
31. FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457 [No Abstract] [Full Text] [Related]
32. A risk-benefit assessment of irinotecan in solid tumours. Siu LL; Rowinsky EK Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386 [TBL] [Abstract][Full Text] [Related]
34. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238 [TBL] [Abstract][Full Text] [Related]
35. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis. Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491 [TBL] [Abstract][Full Text] [Related]
37. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416 [TBL] [Abstract][Full Text] [Related]